Comparative Pharmacology
Head-to-head clinical analysis: KLOXXADO versus NALMEFENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOXXADO versus NALMEFENE HYDROCHLORIDE.
KLOXXADO vs NALMEFENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.
Nalmefene is an opioid receptor antagonist with high affinity for mu, kappa, and delta receptors, and partial agonist activity at kappa receptors.
5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.
18 mcg intranasally once, repeated after 2-3 minutes if needed; maximum 2 doses (36 mcg) per episode. Alternatively, 0.5 mg subcutaneously or intramuscularly once, repeated after 2-3 minutes if needed; maximum 1.5 mg per episode.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); clinical context: short half-life supports rapid reversal of opioid effects but requires monitoring for renarcotization, especially with long-acting opioids.
Terminal elimination half-life: ~10.8 hours (range 8–13 hours); clinically supports twice-daily dosing or use in alcohol use disorder
Hepatic metabolism primarily via CYP3A4 to inactive metabolites; renal excretion accounts for <1% of unchanged drug; fecal excretion accounts for approximately 50-60% of the dose as metabolites.
Primarily renal (approximately 50% unchanged drug); biliary/fecal excretion accounts for ~20%
Category C
Category C
Opioid Antagonist
Opioid Antagonist